While these findings collectively support that inhibitors of the DNA damage response enhance the radiation-induced innate immune response in tumor cells, it is likely, given the differential abilities of ATM, ATR, and DNA-PK to modulate DNA repair, replication stress, and cell cycle checkpoints, that therapies targeting these proteins will also vary in terms of their ability to induce antitumoral immunity. This evidence concerns the gene ATM and neoplasm.